Author

Monica Patterson

Observed names: Monica M Patterson, Monica Marie Patterson

Institution: Pfizer (United States)

Observed institutions: Northeastern University, Pfizer (United States), Scorpion Therapeutics (United States)

OpenAlex ID: A5000546149

Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma

2025 · Nancy L. Bartlett, Uwe Hahn, et al. · Journal of Clinical Oncology · 49

Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma

2025 · Nancy L. Bartlett, Uwe Hahn, et al. · Future Oncology · 2

1024. Evaluation of Atovaquone Prescribing for Pneumocystis jiroveci Pneumonia (PJP) Prophylaxis

2019 · Muneerah Aleissa, David Kubiak, et al. · Open Forum Infectious Diseases · 1

Msr118 Assessing the Impact of Inclusion of Patients With Missing Eastern Cooperative Oncology Group (ecog) Performance Status in Real-world Outcomes of Third-line or Later (3l+) Diffuse Large B-cell Lymphoma (dlbcl)

2026 · Michael Wallington, Yong Chen, et al. · Value in Health

SA42 Feasibility Assessment of a Real-World Comparator Cohort Using Multiple Qualifying Index Lines of Therapy (LOTs) in Third-Line or Later (3L+) Diffuse Large B-cell Lymphoma (DLBCL)

2025 · Michael Wallington, Yong Chen, et al. · Value in Health

Analysis of real-world overall survival (rwOS) among patients with third-line or later (3L+) diffuse large B-cell lymphoma (DLBCL) with multiple qualifying index dates treated in the United States

2025 · Michael Wallington, Yong Chen, et al. · Blood

Safety characteristics of brentuximab vedotin among patient subgroups: Insightsfrom pooled clinical trial database

2025 · Heather Ward, Wamiq Zaidi, et al. · Blood

Efficacy of brentuximab vedotin combination treatment in patients with relapsed or refractory diffuse large B-cell lymphoma with CD30 <1% expression

2025 · Grzegorz Nowakowski, Rebecca King, et al. · Blood

ABCL-1118: Durability of Complete Responses in Patients From the ECHELON-3 Study

2025 · Christopher A. Yasenchak, Nancy L. Bartlett, et al. · Clinical Lymphoma Myeloma & Leukemia

POSTER: ABCL-1118 Durability of Complete Responses in Patients From the ECHELON-3 Study

2025 · Christopher A. Yasenchak, Nancy L. Bartlett, et al. · Clinical Lymphoma Myeloma & Leukemia

Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

2024 · Uwe Hahn, Nancy L. Bartlett, et al. · Blood

Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

2024 · Nancy L. Bartlett, Jeong-A Kim, et al. · Blood

Durability of Complete Responses in Patients from the ECHELON-3 Study

2024 · Christopher Yasenchak, Nancy L. Bartlett, et al. · Blood

Abstract PO1-20-04: STX-478-101: A phase 1/2, first-in-human study of STX-478 monotherapy or in combination with fulvestrant in patients with breast cancer or other advanced solid tumors (trial in progress)

2024 · Alberto Montero, Douglas Orr, et al. · Cancer Research

1412. Spontaneous Intramedullary Abscess from Streptococcus anginosus Group: A Case Report and a Review of the Literature

2019 · Monica M Patterson, Muneerah Aleissa, et al. · Open Forum Infectious Diseases

Works count: 15

Citation count: 52

H-index: 2

I10-index: 1